Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
Open Access
- 27 March 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70679
Abstract
Background: Immune‐related eosinophilia has emerged as an adverse event associated with immune checkpoint inhibitors (ICIs). Its prevalence, severity, duration, clinical significance, diagnostic approach, and management remain unexplored.Methods: We conducted a retrospective review of melanoma patient records at a university referral center. Our analysis encompassed the incidence of eosinophilia, baseline disease characteristics, treatment modalities, peak eosinophil counts, associated symptoms, diagnostic procedures, management strategies, disease course, and prognostic implications.Results: A total of 308 patients were included. Eosinophilia was present in 21.4%, and there was no association with gender, age, histologic type, stage, or BRAF mutation status. The median time interval from treatment initiation to the eosinophilia onset was 56 days, the median eosinophil count at first presentation was 0.70 × 109/L, and the maximum eosinophil count was 1.02 × 109/L. The rate of eosinophilia was significantly higher in patients treated with nivolumab plus bempegaldesleukin (50.0%), followed by nivolumab plus ipilimumab (21.7%). Symptomatic patients and/or patients with hypereosinophilia were assessed for organ involvement and for the identification of the cause of eosinophilia. Patients requiring medical intervention were managed with corticosteroids or antihistamines. Eosinophilia relapsed in 31.8% when rechallenged. While non‐significant, there was a numeric trend for longer overall survival in patients with eosinophilia (42.6 vs. 27.9 months, p = 0.178).Conclusions: This study marks the first comprehensive approach of the relationship between the type of immunotherapy and the incidence of eosinophilia in melanoma patients. It also delves into the patients' baseline characteristics, diagnostic assessment, management, and prognosis, providing useful guidance for physicians treating patients with ICIs.Keywords
This publication has 26 references indexed in Scilit:
- Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the LiteratureJournal of Immunotherapy, 2018
- Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markersBritish Journal of Cancer, 2017
- Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodiesEuropean Journal of Cancer, 2017
- Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to ImmunotherapyImmunotherapy, 2017
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClinical Cancer Research, 2016
- Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective studyThe Journal of Dermatology, 2016
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabClinical Cancer Research, 2016
- Predictive immune markers in advanced melanoma patients treated with ipilimumabOncoImmunology, 2016
- Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapyBlood, 2014
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survivalAnnals of Oncology, 2013